Analyst Rating Update on Exelixis (EXEL)

Exelixis (EXEL) has an average broker rating of 1.4, which is interpreted as a Strong Buy, as rated by 5 equity analysts. Nonetheless, 4 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Exelixis (EXEL) : The highest level Exelixis (EXEL) is projected to reach is $10 for the short term and the lowest estimate is at $5. The consolidated price target from 3 rating analysts who initiate coverage on the stock is $8.33 and the possibility the share price can swing is $2.89.

For the current week, the company shares have a recommendation consensus of Buy.


Exelixis (NASDAQ:EXEL): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $9.12 and $9.00 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $9.40. The buying momentum continued till the end and the stock did not give up its gains. It closed at $9.39, notching a gain of 2.62% for the day. The total traded volume was 7,416,227 . The stock had closed at $9.15 on the previous day.

Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States. The Companys other programs include metastatic renal cell carcinoma (mRCC), a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL, a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888, a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.